There are currently 16 active clinical trials seeking participants for Primary Sclerosing Cholangitis research studies. The states with the highest number of trials for Primary Sclerosing Cholangitis participants are California, Virginia, Texas and Florida.
Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach
NCT04685200
Recruiting
Background: Primary sclerosing cholangitis is a rare chronic liver disease. It affects the bile ducts of the liver. It can result in bile duct infections, cirrhosis, cancer, and end stage liver disease. Researchers want to learn more about this disease. Objective: To understand the biological causes of primary sclerosing cholangitis. Eligibility: Adults age 18 and older who have primary sclerosing cholangitis. Design: Participants will be screened with a medical history, physical exam, a... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
05/07/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Primary Sclerosing Cholangitis
Register for Updates
Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC
NCT06197308
Recruiting
This pilot clinical trial will evaluate the initial safety and feasibility of microbiota transplant therapy (MTT) inpatients with primary sclerosing cholangitis (PSC). This trial will inform development of future trials in treatment of PSC.
Gender:
ALL
Ages:
Between 18 years and 76 years
Trial Updated:
05/05/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Primary Sclerosing Cholangitis
Register for Updates
Detoxification of the Liver In PSC (Dolphin)
NCT05835505
Recruiting
This study is a clinical trial being done to investigate the efficacy of drug BRS201 (hydroxocobalamin) as a treatment in patients with primary sclerosing cholangitis. Participation in this study will take 8 weeks long and the study is structured as a cross-over study in which participants will take the study drug for 4 weeks and a placebo drug for 4 weeks in a randomized order in the form of an oral medication. Participation may also involve receiving an IV dose of the medication. The study wil... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/28/2025
Locations: Brigham and Women's Hospital, Chestnut Hill, Massachusetts
Conditions: Primary Sclerosing Cholangitis
Register for Updates
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
NCT04663308
Recruiting
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/15/2025
Locations: Southern California Research Center, Coronado, California +101 locations
Conditions: Primary Sclerosing Cholangitis
Register for Updates
Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study
NCT05912387
Recruiting
PSC is a liver disease that has no medical cure. Patients with PSC are at a greatly increased risk of cancer and infection. Additionally, many patients require a liver transplant. Progress towards a cure has been severely limited by an incomplete understanding of why patients develop PSC. The investigators aim to close this gap by conducting a pilot human study in patients with PSC, using statin therapy as a model
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/14/2025
Locations: Stanford University, Stanford, California
Conditions: Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases
Register for Updates
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
NCT06905054
Recruiting
This study aims to determine the efficacy of 36 months once-daily fenofibrate in preventing clinically-detectable recurrence of primary sclerosing cholangitis after liver transplantation, compared with a historical control cohort that was not treated with
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/14/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Primary Sclerosing Cholangitis, Liver Transplant, Complications, PSC, Biliary Strictures
Register for Updates
Biobank for Cholestatic Liver Diseases.
NCT03445585
Recruiting
This study is a biobank of specimens and clinical data for use in current and future research to better understand the cholestatic liver diseases primary biliary cirrhosis/cholangitis (PBC) and primary sclerosing cholangitis (PSC).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
02/10/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, Cholangiocarcinoma, Liver Cancer
Register for Updates
Characterization of Biliary Cell-derived Organoids from Bile of PSC and Non-PSC Patients
NCT04753996
Recruiting
The purpose of this research is to create a collection of bile, bile duct brushings and medical information from people with Primary Sclerosing Cholangitis (PSC) and controls to learn more about changes that occur in the liver.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
02/10/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Primary Sclerosing Cholangitis, PSC, Cholangiocarcinoma
Register for Updates
A-LiNK: Improving Outcomes in Autoimmune Liver Disease
NCT05750498
Recruiting
The Autoimmune Liver disease Network for Kids (A-LiNK) is a multi-institutional group with the mission to deliver the best care to kids with pediatric autoimmune liver disease (AILD). This study will establish a shared clinical registry and a learning health network for the participating sites focusing on collecting and transmitting clinical measurement data, information about processes, and participation in an improvement collaborative. Pediatric Autoimmune Hepatitis (AIH) and Primary Scleros... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/09/2024
Locations: Stanford University, Palo Alto, California +7 locations
Conditions: Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Register for Updates
MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
NCT03175471
Recruiting
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factors for chronic liver disease among adolescents. In all these conditions, autoimmune lymphocyte responses are thought to orchestrate inflammatory injury against hepatocytes (primarily in AIH) or cholangiocytes (in PSC). In this proposal we aim to evaluate the Magnetic Resonance Imaging (MRI) modalities; MR cholangiopancreatography (MRCP) and MR elastogr... Read More
Gender:
ALL
Ages:
Between 6 years and 23 years
Trial Updated:
12/09/2024
Locations: Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio
Conditions: Autoimmune Liver Disease, Primary Sclerosing Cholangitis, Autoimmune Hepatitis
Register for Updates
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
NCT03178630
Recruiting
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factor for chronic liver disease among adolescents. This is a longitudinal study to identify surrogate endpoints with an accurate predictive value for the progression of hepatobiliary damage in subjects with pediatric onset AILD. This study will involve collection of MRI-based data at the time of enrollment and at year 1 and 2 of follow up, and collection o... Read More
Gender:
ALL
Ages:
Between 6 years and 23 years
Trial Updated:
12/09/2024
Locations: Cincinnati Children's Hospital and Medical Center, Cincinnati, Ohio
Conditions: Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Register for Updates
Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.
NCT05295680
Recruiting
Primary objective: To evaluate the efficacy of hymecromone plus standard of care compared with standard of care alone in the treatment of adolescents and adults with primary sclerosing cholangitis (PSC). Secondary objectives: To evaluate the change in Alkaline Phosphatase (ALP) from baseline to 6 months post-treatment following treatment with hymecromone plus standard of care compared with standard of care. To evaluate changes in biomarkers of PSC disease during hymecromone treatment, namely:... Read More
Gender:
ALL
Ages:
Between 14 years and 75 years
Trial Updated:
11/24/2024
Locations: Stanford Clinic, Redwood City, California +1 locations
Conditions: Primary Sclerosing Cholangitis
Register for Updates